FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384120188> ?p ?o ?g. }

• W4384120188 endingPage "e2323219" @default.
• W4384120188 startingPage "e2323219" @default.
• W4384120188 abstract "Importance SARS-CoV-2 infection has had significant effects on the health of people worldwide. Whether SARS-CoV-2 infection during controlled ovarian stimulation (COS) is associated with laboratory outcomes in assisted reproductive technology remains unclear. Objective To investigate the association between SARS-CoV-2 infection during COS with oocyte- and embryo-related outcomes. Design, Setting, and Participants A multicenter cohort study was conducted of couples undergoing assisted reproductive technology treatments in 7 reproductive centers in 4 provinces in China from October 1, 2022, to December 31, 2022. All couples received nucleic acid testing for SARS-CoV-2 during COS. The SARS-CoV-2–positive group included couples in which either partner was infected with SARS-CoV-2. The SARS-CoV-2–negative group comprised couples without infection. Exposure In the SARS-CoV-2–positive group, either partner was infected with SARS-CoV-2 during COS, defined as a positive test result for the SARS-CoV-2 antigen. Main Outcomes and Measures Primary outcomes were the available embryo and blastocyst and top-quality embryo and blastocyst rates. Secondary outcomes were the number of oocytes retrieved, the mature oocyte rate, normal fertilization (2 pronuclei observed on day 1 after insemination [2PN]), oocyte degeneration, 2PN cleavage, and blastocyst formation rates. Results A total of 585 heterosexual couples with infertility participated in the study (median [IQR] age for female partners, 33 [30-37] years), with 135 couples in the SARS-CoV-2–positive group and 450 in the SARS-CoV-2–negative group. The characteristics of the groups were similar. The SARS-CoV-2–positive group had a significantly lower top-quality embryo rate (odds ratio [OR], 0.83; 95% CI, 0.71-0.96), top-quality blastocyst rate (OR, 0.59; 95% CI, 0.45-0.77), available blastocyst rate (OR, 0.70; 95% CI, 0.59-0.82), and blastocyst formation rate (OR, 0.61; 95% CI, 0.52-0.71) than the SARS-CoV-2–negative group. Analysis of the associations of infection by sex showed that the female positive group had impaired oocyte and embryo quality regarding mature oocyte rate, 2PN cleavage rate, top-quality embryo rate, blastocyst formation rate, available blastocyst rate, and top-quality blastocyst rate compared with the SARS-CoV-2–negative group. Compared with the SARS-CoV-2–negative group, the male positive group and the group of couples with both positive partners had significantly decreased available blastocyst rate, top-quality blastocyst rate, and blastocyst formation rate compared with the SARS-CoV-2 negative group. Conclusions and Relevance In this cohort study, SARS-CoV-2 infection during COS was negatively associated with embryo and blastocyst quality. Reproductive physicians should be more attentive to patients with SARS-CoV-2 infection during COS and should give couples who have been infected adequate counseling." @default.
• W4384120188 created "2023-07-14" @default.
• W4384120188 creator A5000694109 @default.
• W4384120188 creator A5002667544 @default.
• W4384120188 creator A5011432307 @default.
• W4384120188 creator A5012667393 @default.
• W4384120188 creator A5014086221 @default.
• W4384120188 creator A5015592432 @default.
• W4384120188 creator A5018167422 @default.
• W4384120188 creator A5025705934 @default.
• W4384120188 creator A5042275051 @default.
• W4384120188 creator A5042772858 @default.
• W4384120188 creator A5043654650 @default.
• W4384120188 creator A5048692686 @default.
• W4384120188 creator A5079857928 @default.
• W4384120188 creator A5081209056 @default.
• W4384120188 date "2023-07-13" @default.
• W4384120188 modified "2023-09-27" @default.
• W4384120188 title "Association of SARS-CoV-2 Infection During Controlled Ovarian Stimulation With Oocyte- and Embryo-Related Outcomes" @default.
• W4384120188 cites W2124656409 @default.
• W4384120188 cites W2135935849 @default.
• W4384120188 cites W2524587664 @default.
• W4384120188 cites W2971809390 @default.
• W4384120188 cites W3020993161 @default.
• W4384120188 cites W3031095594 @default.
• W4384120188 cites W3032147501 @default.
• W4384120188 cites W3043762389 @default.
• W4384120188 cites W3049417612 @default.
• W4384120188 cites W3114705283 @default.
• W4384120188 cites W3131810785 @default.
• W4384120188 cites W3132251605 @default.
• W4384120188 cites W3155457671 @default.
• W4384120188 cites W3158933705 @default.
• W4384120188 cites W3160051522 @default.
• W4384120188 cites W3162872915 @default.
• W4384120188 cites W3178930625 @default.
• W4384120188 cites W3191847447 @default.
• W4384120188 cites W3208257584 @default.
• W4384120188 cites W4200388178 @default.
• W4384120188 cites W4206514458 @default.
• W4384120188 cites W4210492090 @default.
• W4384120188 cites W4214588706 @default.
• W4384120188 cites W4224987978 @default.
• W4384120188 cites W4226125240 @default.
• W4384120188 cites W4228999201 @default.
• W4384120188 cites W4233187779 @default.
• W4384120188 cites W4241433614 @default.
• W4384120188 cites W4280517420 @default.
• W4384120188 cites W4294583382 @default.
• W4384120188 cites W4308949357 @default.
• W4384120188 cites W4321004188 @default.
• W4384120188 doi "https://doi.org/10.1001/jamanetworkopen.2023.23219" @default.
• W4384120188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37440229" @default.
• W4384120188 hasPublicationYear "2023" @default.
• W4384120188 type Work @default.
• W4384120188 citedByCount "0" @default.
• W4384120188 crossrefType "journal-article" @default.
• W4384120188 hasAuthorship W4384120188A5000694109 @default.
• W4384120188 hasAuthorship W4384120188A5002667544 @default.
• W4384120188 hasAuthorship W4384120188A5011432307 @default.
• W4384120188 hasAuthorship W4384120188A5012667393 @default.
• W4384120188 hasAuthorship W4384120188A5014086221 @default.
• W4384120188 hasAuthorship W4384120188A5015592432 @default.
• W4384120188 hasAuthorship W4384120188A5018167422 @default.
• W4384120188 hasAuthorship W4384120188A5025705934 @default.
• W4384120188 hasAuthorship W4384120188A5042275051 @default.
• W4384120188 hasAuthorship W4384120188A5042772858 @default.
• W4384120188 hasAuthorship W4384120188A5043654650 @default.
• W4384120188 hasAuthorship W4384120188A5048692686 @default.
• W4384120188 hasAuthorship W4384120188A5079857928 @default.
• W4384120188 hasAuthorship W4384120188A5081209056 @default.
• W4384120188 hasBestOaLocation W43841201881 @default.
• W4384120188 hasConcept C110758877 @default.
• W4384120188 hasConcept C16685009 @default.
• W4384120188 hasConcept C196843134 @default.
• W4384120188 hasConcept C2776210078 @default.
• W4384120188 hasConcept C2776690073 @default.
• W4384120188 hasConcept C2777542035 @default.
• W4384120188 hasConcept C2777688143 @default.
• W4384120188 hasConcept C2778177303 @default.
• W4384120188 hasConcept C2779234561 @default.
• W4384120188 hasConcept C28748434 @default.
• W4384120188 hasConcept C29456083 @default.
• W4384120188 hasConcept C500014431 @default.
• W4384120188 hasConcept C54355233 @default.
• W4384120188 hasConcept C71924100 @default.
• W4384120188 hasConcept C86803240 @default.
• W4384120188 hasConcept C87073359 @default.
• W4384120188 hasConceptScore W4384120188C110758877 @default.
• W4384120188 hasConceptScore W4384120188C16685009 @default.
• W4384120188 hasConceptScore W4384120188C196843134 @default.
• W4384120188 hasConceptScore W4384120188C2776210078 @default.
• W4384120188 hasConceptScore W4384120188C2776690073 @default.
• W4384120188 hasConceptScore W4384120188C2777542035 @default.
• W4384120188 hasConceptScore W4384120188C2777688143 @default.
• W4384120188 hasConceptScore W4384120188C2778177303 @default.
• W4384120188 hasConceptScore W4384120188C2779234561 @default.
• W4384120188 hasConceptScore W4384120188C28748434 @default.

• next